Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Phase 1: Advanced or Refractory Solid Tumours”

219 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 219 results

Early research (Phase 1)Study completedNCT00004059
What this trial is testing

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT02451553
What this trial is testing

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmBile Duct CarcinomaRecurrent Malignant Solid Neoplasm+4 more
University of Washington 41
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)Study completedNCT00567931
What this trial is testing

1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 52
Testing effectiveness (Phase 2)Looking for participantsNCT04390737
What this trial is testing

Evaluate the Safety and Clinical Activity of HH2853

Who this might be right for
FL LymphomaEpithelioid SarcomaPeripheral T Cell Lymphoma+1 more
Haihe Biopharma Co., Ltd. 254
Early research (Phase 1)Study completedNCT01976741
What this trial is testing

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Who this might be right for
Neoplasms
Bayer 168
Testing effectiveness (Phase 2)Study completedNCT01949688
What this trial is testing

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors

Who this might be right for
Solid Tumors
Shiga University 26
Early research (Phase 1)Study completedNCT00207012
What this trial is testing

MAD Refractory: Solid Tumor QD w/o Break

Who this might be right for
HER2 or EGFR Expressing Advanced Solid Malignancies
Bristol-Myers Squibb 45
Early research (Phase 1)UnknownNCT05564806
What this trial is testing

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Advanced Solid TumorsRelapsed Or Refractory Non-Hodgkin Lymphoma
Eucure (Beijing) Biopharma Co., Ltd 38
Early research (Phase 1)Study completedNCT05501821
What this trial is testing

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Who this might be right for
Advanced Solid Tumor Malignancy
Kling Biotherapeutics B.V. 16
Early research (Phase 1)Study completedNCT02743637
What this trial is testing

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

Who this might be right for
Advanced MalignancyAdvanced Solid TumorsNeoplasm+1 more
SynDevRx, Inc. 32
Early research (Phase 1)Study completedNCT01628640
What this trial is testing

Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmHepatocellular Carcinoma
Mayo Clinic 17
Early research (Phase 1)Ended earlyNCT02508441
What this trial is testing

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

Who this might be right for
Advanced Unresectable Solid Tumors
Andes Biotechnologies 22
Early research (Phase 1)Study completedNCT00996957
What this trial is testing

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Advanced Solid TumorsMultiple Myeloma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 37
Early research (Phase 1)Study completedNCT00816361
What this trial is testing

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Who this might be right for
Cancer
MedImmune LLC 43
Early research (Phase 1)Study completedNCT00608361
What this trial is testing

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Who this might be right for
Adult Acute Lymphoblastic Leukemia in RemissionAdult B Acute Lymphoblastic LeukemiaAdult Hepatocellular Carcinoma+82 more
National Cancer Institute (NCI) 80
Early research (Phase 1)Study completedNCT02628574
What this trial is testing

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Who this might be right for
Solid Tumors
Leap Therapeutics, Inc. 109
Early research (Phase 1)Ended earlyNCT00651365
What this trial is testing

A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.

Who this might be right for
Neoplasms
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 14
Early research (Phase 1)Study completedNCT03934814
What this trial is testing

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Who this might be right for
Solid TumorLymphoma
I-Mab Biopharma US Limited 98
Load More Results